Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
Authors:
Open Access
- 24 August 2011
- journal article
- research article
- Published by Springer Nature in Pituitary
- Vol. 15 (3) , 398-404
Abstract
Long-acting somatostatin analogs are frequently used as adjuvant treatment of acromegaly patients after noncurative surgery. This sudy aims to compare the efficacy of octreotide long-acting release (OCT) and lanreotide Autogel (LAN) in acromegaly patients. Sixty-eight patients not cured by transsphenoidal endoscopic or microscopic pituitary surgery between 2003 and 2009 were retrospectively analyzed (25 men; 43 women; mean age 41.1 ± 10.9 years [range 18–65 years]). The patients were assigned randomly to OCT (n = 36) and LAN (n = 32) groups. Evaluations included insulin-like growth factor I (IGF-I) and growth hormone (GH) after oral glucose tolerance test (OGTT) 3, 6, 12 and 18 months after starting medical treatment; pituitary magnetic resonance imaging was performed before treatment and after 3 and 12 months. Patients achieving IGF-I levels within the age and gender normal range and GH level 3) in the LAN and OCT groups were similar in the post-operative period before initiation of medical treatment. A statistically significant decrease in GH and IGF-I levels was obtained for both treatment groups at each follow-up visit compared to the previous value. Tumor shrinkage after 12 months of treatment was statistically significant in both groups but the percentage tumor shrinkage (28.5% vs. 34.9%, P = 0.166) and rate of patients achieving biochemical cure (63.9 and 78.1%, P = 0.454) were similar between OCT and LAN groups, respectively. OCT and LAN treatment options have similar efficacy for ensuring biochemical cure and tumor shrinkage in acromegaly patients who had noncurative surgery.Keywords
This publication has 40 references indexed in Scilit:
- Significant tumour shrinkage after 12 months of lanreotide Autogel‐120 mg treatment given first‐line in acromegalyClinical Endocrinology, 2009
- Somatostatin agonists for treatment of acromegalyMolecular and Cellular Endocrinology, 2008
- A 12‐month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long‐acting repeatable on GH and IGF‐l in patients with acromegalyClinical Endocrinology, 2007
- The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenomaClinical Endocrinology, 2007
- Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patientsPituitary, 2007
- Efficacy of a slow‐release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal studyClinical Endocrinology, 2007
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Long‐term (up to 18 years) effects on GH/IGF‐1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH‐secreting pituitary adenoma responsive to SSTaClinical Endocrinology, 2007
- Slow release lanreotide treatment in acromegalic patients previously normalized by octreotideThe Journal of Clinical Endocrinology & Metabolism, 1994
- AcromegalyNew England Journal of Medicine, 1990